UK: A Court Of Justice Reference Breathes Life Into Sigma's Parallel Importation Appeal

Last Updated: 11 February 2014
Article by Stephen Duffield and Dr. Hugh Goodfellow

The Court of Appeal has recently handed down a decision indicating its intention to refer questions relating to the Specific Mechanism to the Court of Justice (Europe's highest court; the CJEU) on an appeal from the Patents County Court.

Legal background

One of the foundations of the European Union is the limitation of barriers to trade between member states, so as to allow free circulation of goods throughout the single market. Under the relevant rules, the owner of an intellectual property right in a first member state cannot use its rights to prevent the importation of goods from a second member state, if the goods were entered into circulation in the single market by or with the consent of the rights holder.

Importation from one member state into another is known as parallel importing. It is typically undertaken to exploit price differences between member states, for example where a pharmaceutical product is protected by a patent or supplementary protection certificate (SPC) in one state but is not in another (where prices may be lower due to generic competition).

However, where the exporting member state is one of the more recent joiners to the EU, a derogation from the principle of free movement is permitted for pharmaceutical products in certain circumstances. This is due to the Specific Mechanism which was written into the accession treaty of these states:

SPECIFIC MECHANISM

"With regard to the Czech Republic, Estonia, Latvia, Lithuania, Hungary, Poland, Slovenia or Slovakia, the holder, or his beneficiary, of a patent or supplementary protection certificate for a pharmaceutical product filed in a Member State at a time when such protection could not be obtained in one of the abovementioned new Member States for that product, may rely on the rights granted by that patent or supplementary protection certificate in order to prevent the import and marketing of that product in the Member State or States where the product in question enjoys patent protection or supplementary protection, even if the product was put on the market in that new Member State for the first time by him or with his consent.

Any person intending to import or market a pharmaceutical product covered by the above paragraph in a Member State where the product enjoys patent or supplementary protection shall demonstrate to the competent authorities in the application regarding that import that one month's prior notification has been given to the holder or beneficiary of such protection."

Similar provisions also exist for some other states, e.g., Bulgaria and Romania.

Thus, if equivalent patent or SPC protection could not have been obtained in the new member state at the time the patent or SPC was filed in the importing member state, the rights holder can prevent the import of pharmaceutical products from the new member state even if they were put onto the market in the new member state by or with the rights holder's consent.

For a pharmaceutical product, parallel importation also needs to be approved by the competent regulatory authority, which is concerned with the product's safety and efficacy. The authority grants a parallel import licence which allows the importer to take advantage of an existing market authorisation (i.e. an approval that the pharmaceutical product is safe and effective), and thus allows marketing of the imported product on that basis. However, as set out in the second paragraph of the above quotation, where parallel importation might be prevented under the Specific Mechanism, the party intending to import the pharmaceutical product is additionally required to demonstrate to the regulatory authority that it has given one month's notification to the rights holder in the country of import.

Factual Background

Merck Canada Inc. started an action for infringement of a UK patent and a UK SPC (covering the active ingredient in the asthma treatment Singulair®) by Sigma Pharmaceuticals PLC, which was importing Singulair® from Poland into the UK. Sigma said that it had notified Merck of its intention to import in June 2009. On the basis that it received no response, Sigma began to import Singulair®. In December 2010, Merck notified Sigma that it objected. Sigma immediately ceased its activities. Merck in any case sued for the acts conducted by Sigma prior to ceasing its activities.


At first instance, the judge decided in Merck's favour. He granted an injunction and ordered Sigma to deliver up its unsold stocks of Singulair®. Before the Court of Appeal, Sigma argued that it was not liable for infringement prior to Merck's objection because Merck should have responded within the month set by the letter of June 2009. Sigma also argued that the lack of response prevented Merck from exerting its rights by estoppel under English law.


Merck argued that the Specific Mechanism did not require that it must exercise its rights on notice from the prospective importer and that, in any case, Sigma had failed to fulfil its obligations under the Specific Mechanism because the correct legal entity in the Merck group of companies had not been notified by the correct legal entity in the Sigma group of companies. Merck also argued that its silence did not satisfy the requirements for estoppel under English law.

The Judgment

The Court of Appeal agreed with the first instance judge that there was no estoppel resulting from Merck's failure to respond to Sigma's notification letter. It also affirmed that the judge was entitled to make the order for delivery up, if his finding of infringement was correct.

It appeared more sympathetic, however, to Sigma's arguments on the workings of the Specific Mechanism than the judge had been, noting that the "free movement rule is one of the core principles of the European single market and any derogation from it must be interpreted strictly". Even though the court appeared to favour Sigma's arguments, it opined that the issues were far from acte clair. In this situation it deemed that, before it could decide the appeal, a reference to the CJEU was appropriate in order to clarify the workings of the Specific Mechanism on the following issues:

  1. The conditions which must be satisfied before a patent holder may bring infringement proceedings under the Specific Mechanism and, in particular, whether the derogation confers upon the patent holder an option of preventing imports falling in its scope; and whether the derogation is inapplicable unless and until the patent holder demonstrates his intention to exercise that option.
  2. The identity of the person who must give the notice under the Specific Mechanism and, in particular, whether a notification is compliant if it is given by an applicant for regulatory approval in the Member State into which the products are to be imported rather than the importer; and whether it makes any difference if notification and importation are performed by different legal entities within a group of companies.
  3. The identity of the person to whom notice must be given, and whether when a group of companies form a single economic unit comprising a number of legal entities, it is sufficient if the notification is addressed to a legal entity which is the operating subsidiary and marketing authorisation holder in the Member State of importation rather than the entity within the group which has legal ownership of or an exclusive licence under the intellectual property right. This issue also raised the subsidiary question as to whether a notification which is otherwise compliant is rendered non compliant if it is addressed to the "the Manager, Regulatory Affairs".

Although the exact form of the questions has yet to be decided upon, the Court of Appeal has instructed the parties to draft questions and a reference to the CJEU. The court considered the issues in the case to be worthy of a reference to the CJEU because the Specific Mechanism will continue to apply until 2019.

Further clarification of the issues raised in this case will be of interest to both originator pharmaceutical companies and parallel importers alike.

Need advice?

Carpmaels & Ransford LLP is a leading firm of European patent and trade mark attorneys based in London. For more information about our firm and our practice, please visit our website at www.carpmaels.com.

This Briefing Note was first published in the IAM IP Newsletter.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.